CBG (Cannabigerol)
Also known as Cannabigerol
Non-psychoactive cannabinoid from which THC and CBD are enzymatically derived in the cannabis plant; early preclinical research suggests antibacterial, anti-inflammatory, and neuroprotective activity, though human trial data remain limited.
Reported side effects:No drug-related adverse events in a single ascending-dose study of oral cannabigerol 25-200 mg in 12 healthy adults; subjective effects minimal apart from small changes in ratings (e.g. increased appetite ratings at 200 mg); liver function tests did not exceed the upper limit of normal after the highest acute doses. Single-dose data only — chronic dosing has not been characterised.In a double-blind crossover field trial of 20 mg cannabigerol in 34 healthy adults, no subjective drug effects or impairment were detected
Be careful if: pregnant, breastfeeding, some medical situations
Suspect a side effect? Report it to the MHRA Yellow Card scheme ↗
What the research actually shows
We link to relevant studies and leave interpretation to you and your healthcare professional.
Safety and considerations
What sources report about side effects, who should be careful, and medicines to ask about first.
Reported side effects
| Reported effect | How often | Basis | Sources |
|---|---|---|---|
| No drug-related adverse events in a single ascending-dose study of oral cannabigerol 25-200 mg in 12 healthy adults; subjective effects minimal apart from small changes in ratings (e.g. increased appetite ratings at 200 mg); liver function tests did not exceed the upper limit of normal after the highest acute doses. Single-dose data only — chronic dosing has not been characterised. | unknown | Listed by PubMed corpus rows (PubMed 42575778, 39003387) | Wolinsky D, et al. Safety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults. J Pharmacol Exp Ther 2026;393(8):104984 (PMID 42575778)Cuttler C, Stueber A, Cooper ZD, Russo E. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Sci Rep 2024;14(1):16163 (PMID 39003387) |
| In a double-blind crossover field trial of 20 mg cannabigerol in 34 healthy adults, no subjective drug effects or impairment were detected | unknown | Listed by PubMed corpus rows (PubMed 39003387) | Cuttler C, Stueber A, Cooper ZD, Russo E. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Sci Rep 2024;14(1):16163 (PMID 39003387) |
Be careful if you…
| Applies to | What sources say | Sources |
|---|---|---|
| pregnant | No pregnancy data — cannabigerol has been studied acutely only in healthy non-pregnant adults (n=12 and n=34). | Wolinsky D, et al. Safety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults. J Pharmacol Exp Ther 2026;393(8):104984 (PMID 42575778) |
| breastfeeding | No breastfeeding data located; safety while breastfeeding is not established. | Wolinsky D, et al. Safety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults. J Pharmacol Exp Ther 2026;393(8):104984 (PMID 42575778) |
| some medical situations | Products sold as CBG are not assessed medicines in the UK; NHS notes most cannabis products sold online without a prescription are likely illegal to possess, may contain THC, and are of unknown quality. | Medical cannabis (and cannabis oils) — NHS medicines page, last reviewed 27 May 2022 |
Sources
Wolinsky D, et al. Safety, pharmacodynamics, and pharmacokinetics of oral cannabigerol in healthy adults. J Pharmacol Exp Ther 2026;393(8):104984 (PMID 42575778)Cuttler C, Stueber A, Cooper ZD, Russo E. Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial. Sci Rep 2024;14(1):16163 (PMID 39003387)Medical cannabis (and cannabis oils) — NHS medicines page, last reviewed 27 May 2022
Suggested uses (unproven)
Where people report using it and what trials suggest
- Insufficient evidenceAppetite, inflammation, mood (animal/cell-culture only)
Where the evidence is negative
Common claims the trials do not support
- No published human RCTs for any CBG indication as of 2026.
- Bladder/pain claims trace to rodent work.
Cannabigerol — the 'mother cannabinoid'. Currently preclinical on nearly everything; consumer claims run years ahead of human data.
Evidence grades reflect study quality and consistency, not marketing claims.
Ordered by strength of evidence, then result direction.
01The Effects of Cannabinoids on Pro- and Anti-Inflammatory Cytokines: A Systematic Review of In Vivo StudiesHenshaw FR, et al. · Cannabis and cannabinoid research · 2021PMID 33998900 ↗02The Use of Cannabinoids in Colitis: A Systematic Review and Meta-AnalysisCouch DG, et al. · Inflammatory bowel diseases · 2018PMID 29562280 ↗03Immunomodulatory effects of a mycelium extract of Cordyceps (Paecilomyces hepiali; CBG-CS-2): a randomized and double-blind clinical trialJung SJ, et al. · BMC complementary and alternative medicine · 2019PMID 30925876 ↗04Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialWallentin L, et al. · Circulation · 2014PMID 25294786 ↗05A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal womenShifren JL, et al. · The Journal of clinical endocrinology and metabolism · 2008PMID 18303079 ↗06Changes in androgens during treatment with four low-dose contraceptivesCoenen CM, et al. · Contraception · 1996PMID 8689882 ↗Show all 11 studies
Published research summaries are unavailable.
Why people look into CBG (Cannabigerol) — and what they report
Associated conditions and community-reported outcomes, wrapped together on one page. Aggregates appear only once enough reports arrive.
Where to get CBG (Cannabigerol) (UK)
How this compound is sold in the UK, and where our readers typically find it.
Retailer search links — we may earn commission on purchases at no cost to you. Commission never affects our evidence ratings.
In the UK, CBD products fall under the FSA novel foods list — buy from retailers listing an FSA-assessed product.